HEMLIBRA® is approved for hemophilia A with or without FVIII inhibitors

Indication

HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

Efficacy Endpoints for Patients Without Inhibitors

Learn about the primary and secondary results for patients without factor VIII inhibitors

Dosing Calculator 

Help calculate the dosage for your HEMLIBRA patient

Mechanism of Action

How HEMLIBRA may work in patients with hemophilia A with or without FVIII inhibitors